Press "Enter" to skip to content

Zogenix’s seizure drug filing fails to pass U.S. FDA scrutiny

The U.S. Food and Drug Administration on Monday refused to fully review the marketing application for Zogenix Inc’s treatment for seizures associated with Dravet syndrome, a rare form of childhood epilepsy.

Also Read:   Judge summons drug company CEOs to discuss opioid settlement: source